[CAS NO. 133162-24-0] β-Aminoarteether
PRODUCTS SPECIFICATIONS [133162-24-0]
DESCRIPTION [133162-24-0]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 327.42 |
| Molecular Formula | C17H29NO5 |
| SMILES | C[C@@H]1[C@@](CC[C@H]2C)([H])[C@@]([C@@]2([H])CC3)(OO4)[C@@](O[C@@H]1OCCN)([H])O[C@@]34C |
Summary
β-Aminoarteether (SM934 free base) is an Artemisinin derivative with orally active. β-Aminoarteether can be used for inflammation and autoimmune disease research , such as lupus diseases [1] .
In Vitro
β-Aminoarteether (SM934;10 µM; 24 hours) treatment directly enhances
IL-10
production and suppresses IL-12/23p40 production in primary peritoneal macrophages with
IFN-γ
stimulation
[1]
.
In vitro, β-Aminoarteether (SM934) could suppress the Th1 and Th17 polarization, but exerted no influence on Treg differentiation
[1]
.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
β-Aminoarteether (SM934; 1-10 mg/kg; oral administration; daliy; for 3 months) treatment significantly delays the progression of glomerulonephritis and increases the survival rate of NZB/W F1 mice. β-Aminoarteether treatment promots the IL-10 production of macrophages from NZB/W F1 mice [1] .
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Female NZB/W F1 mice (Six and half months old) [1] |
| Dosage: | 1 mg/kg, 3 mg/kg, and 10 mg/kg |
| Administration: | Oral administration; daliy; for 3 months |
| Result: | Significantly delayed the progression of glomerulonephritis and increased the survival rate of NZB/W F1 mice. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03951259 | RenJi Hospital|Jiangsu ZuoYou Medicine Co., Ltd. |
Systemic Lupus Erythematosus
|
July 24, 2019 | Phase 2 |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
References
- [1] Li-Fei Hou, et al. SM934 treated lupus-prone NZB × NZW F1 mice by enhancing macrophage interleukin-10 production and suppressing pathogenic T cell development. PLoS One. 2012;7(2):e32424.
- [2] Yang FM, Fan D, Yang XQ, et al. The artemisinin analog SM934 alleviates dry eye disease in rodent models by regulating TLR4/NF-κB/NLRP3 signaling. Acta Pharmacol Sin. 2021;42(4):593-603.